Catalyst Pharmaceutical Partners Inc. (Nasdaq: CPRX) reported positive
results from a Phase 3 clinical trial of its Lambert-Eaton myasthenia
syndrome treatment Firdapse lifting the stock price 35 cents to $3.34.
Positive study results for Catalyst Pharmaceuticals
September 30, 2014 at 14:13 PM EDT
